Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70742 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Ying Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ividence Inc, Newark, Delaware, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Aims
To characterize the cardiometabolic profiles of oral and subcutaneous glucagon‐like peptide‐1 (GLP‐1) receptor mono‐agonists in adults with overweight or obesity, with or without type 2 diabetes (T2D), using network meta‐analysis (NMA). Materials and Methods PubMed, Embase and CENTRAL were searched (January 2014–November 2025) for randomized controlled trials (RCTs) evaluating GLP‐1 receptor mono‐agonists (semaglutide, liraglutide and orforglipron) in adults with overweight or obesity. The primary outcome was the cardiometabolic efficacy index (CEI), a ranking‐based composite (0 to 1) summarizing performance across seven cardiometabolic endpoints: total body weight loss percentage, triglycerides, HDL cholesterol‐C, LDL‐C, waist circumference, HbA1c and systolic blood pressure. Secondary outcomes included treatment effects for each individual CEI component.
Results
Nineteen RCTs ( N = 13 117) were analysed. Semaglutide 7.2 mg achieved the highest CEI (0.86), followed by orforglipron 36 mg (bioequivalent to Foundayo 17.2 mg tablet) (0.68) and semaglutide 2.4 mg (0.66), all exhibiting placebo‐adjusted weight reductions ≥ 10%. CEI rankings were generally consistent across T2D and non‐T2D subgroups. Among oral formulations in non‐T2D adults, OFG 36 mg showed a CEI comparable to oral semaglutide 25 mg (0.67 vs 0.63).
Conclusions
Higher‐dose GLP‐1 receptor mono‐agonists, particularly semaglutide 7.2 mg and orforglipron 36 mg (Foundayo 17.2 mg tablet), demonstrated the most consistent multidimensional cardiometabolic improvements, although domain‐specific differences were observed across agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ividence Inc, Newark, Delaware, USA.
- UT Southwestern Medical Center, Peter O'Donnell Jr. School of Public Health, Dallas, Texas, USA.
- Pediatric Endocrinology, Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, USA.
- Section of General Pediatrics, Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, USA.
- Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
- Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA.
ORCID-Profile: Yong Chen
Förderung
- Eli Lilly and Company
Zitieren
APA
Lu, Y., Chen, J., Guo, Y., Ding, H., Liu, Y. L., Van Name, M. A., Sharifi, M., Lu, Y., & Chen, Y. (2026). Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70742
Vancouver
Lu Y, Chen J, Guo Y, Ding H, Liu YL, Van Name MA, et al. Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70742
BibTeX
@article{Lu2026,
author = {Lu, Ying and Chen, Jiajie and Guo, Yuqing and Ding, Hao and Liu, Yu-Lun and Van Name, Michelle A and Sharifi, Mona and Lu, Yuan and Chen, Yong},
title = {Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70742}
}
EUVIMED